Circulating Progenitor Cell Count Predicts Microvascular Outcomes in Type 2 Diabetic Patients

Area of Science:

• Endocrinology
• Vascular Biology
• Regenerative Medicine

Background:

• Diabetes mellitus is associated with reduced levels of circulating progenitor cells (CPCs) and endothelial progenitor cells (EPCs).
• These progenitor cells are crucial for vascular repair and their levels correlate inversely with cardiovascular risk.
• Impaired vascular repair mechanisms in diabetes contribute to the development of microvascular complications.

Purpose of the Study:

• To investigate whether baseline levels of CPCs and EPCs can predict the onset or progression of microangiopathy in patients with type 2 diabetes (T2D).
• To assess the predictive value of CPCs/EPCs for specific microvascular complications such as retinopathy, nephropathy, and neuropathy.
• To determine if CPC/EPC levels influence the efficacy of therapeutic interventions for diabetic complications.

Main Methods:

• A pseudoprospective study design with a 3.9-year follow-up was employed.
• 187 patients with type 2 diabetes were recruited from a tertiary referral diabetes outpatient clinic.
• Baseline measurements of circulating CD34(+) CPCs and EPCs were performed, along with collection of demographic, clinical, and medication data. Microangiopathy onset/progression was assessed at follow-up.

Main Results:

• New onset or progression of microvascular complications occurred in 9.5% of patients annually.
• Significantly lower baseline levels of CD34(+) CPCs and EPCs were observed in patients who developed microalbuminuria or any microangiopathy.
• Low CD34(+) CPC or EPC levels independently predicted microvascular complication onset/progression and attenuated the benefits of renin-angiotensin system blockers on microalbuminuria.

Conclusions:

• Circulating progenitor cell levels serve as significant predictors of microvascular outcomes in type 2 diabetic patients.
• CPCs and EPCs are emerging as valuable biomarkers for the overall burden of diabetic complications, including cardiovascular events.
• These findings underscore the potential of targeting progenitor cell function for therapeutic strategies in diabetes management.